ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES USE OF MULTI-CRITERIA DECISION ANALYSIS TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this morning entitled, The Potential and Pitfalls of Using Multi-Criteria Decision Analysis to Support Health Technology Assessment. The session took place at the Society’s 19th Annual European Congress in Vienna, Austria. The workshop was led by discussion leaders that included:
  • Janine A. van Til, PhD, Assistant Professor Preference Research, Health Technology and Services Research, University of Twente, Enschede, The Netherlands
  • Rob Baltussen, PhD, Associate Professor Health Economics, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
  • Michele Tringali, MD, Director, HTA Program, Lombardy Region Health Directorate, Milan, Italy
  • Susanne Schmitz, PhD, Postdoctoral Fellow, Department of Population Health/Health Economics and Evidence Synthesis Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg
The workshop reviewed a number of practical examples to illustrate how health technology assessment (HTA) and reimbursement decisions can be supported with multi-criteria decision analysis (MCDA). The panelists discussed the apparent fit between MCDA and HTA decision making and reviewed the use of a deliberative approach to MCDA that involves stakeholder consultation. Case studies from the Netherlands, Thailand, and Indonesia were presented and results of a retrospective analysis demonstrated potentially important drivers of reimbursement decisions in Ireland and outlined the challenges of using such information to inform an actual MCDA framework. A number of knowledge products on MCDA have been developed by ISPOR’s Multi-Criteria Decision Analysis in Health Care Decision Making Task Force, including the following Task Force Reports published in Value in Health: Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.

ISPOR Launches “HEOR Explained” Microsite

Dec 10, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has launched a new microsite—HEOR Explained—designed to help people better understand how health economics and outcomes research (HEOR) can improve healthcare decisions.

ISPOR Releases Emerging Good Practices Guidance on Quantifying Specialized Knowledge in Healthcare

Nov 6, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that identifies existing structured expert elicitation protocols that can support healthcare decision making and provides important insights on how to choose which protocols may be the most appropriate for different scenarios, such as time-constrained decisions, early-stage technology assessments, and public health policies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×